A number of other analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Bayer from a “hold” rating to a “sell” rating and set a $17.00 price target on the stock. in a report on Wednesday, August 7th. ValuEngine upgraded shares of Bayer from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $17.00.
OTCMKTS BAYRY traded up $0.26 on Friday, reaching $17.81. The company had a trading volume of 37,348 shares, compared to its average volume of 618,755. The company has a quick ratio of 0.92, a current ratio of 1.37 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $65.46 billion, a PE ratio of 10.18, a price-to-earnings-growth ratio of 0.97 and a beta of 1.09. The firm’s 50 day moving average price is $16.93 and its 200 day moving average price is $17.16. Bayer has a 12 month low of $14.61 and a 12 month high of $24.31.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Convertible Shares
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.